PMID- 29770541
OWN - NLM
STAT- MEDLINE
DCOM- 20190205
LR  - 20190730
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 9
DP  - 2018 Sep
TI  - Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose 
      fluctuation in drug-naive Japanese patients with type 2 diabetes mellitus.
PG  - 2274-2281
LID - 10.1111/dom.13364 [doi]
AB  - AIMS: To compare the effect of a dipeptidyl peptidase-4 inhibitor (DPP4-i) and a 
      sulfonylurea (SU) on daily glucose fluctuation in drug-naive Japanese patients 
      with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: A total of 53 
      drug-naive Japanese patients with T2DM (HbA1c, 7.0%-9.0%; fasting plasma glucose, 
      6.1 mmol/L or higher) were randomly assigned to either sitagliptin 50 mg qd or 
      glibenclamide 2.5 mg per day (given in divided doses) in a 1:1 ratio. A 
      continuous glucose monitoring (CGM) device was used to obtain 24-hour glucose 
      profiles for each patient at baseline and at Week 2. The primary study endpoint 
      was change from baseline in mean amplitude of glucose excursion (MAGE) during a 
      24-hour period. A key secondary endpoint was change from baseline in the standard 
      deviation (SD) of 24-hour glucose levels. RESULTS: After 2 weeks of treatment, a 
      numerically greater reduction in MAGE from baseline was observed in the 
      sitagliptin group compared with the glibenclamide group, but the 
      between-treatment difference was not statistically significant (LS mean 
      difference [95% CI]: -0.48 mmol/L [-1.31, 0.34]; P = .245). However, a 
      significantly greater reduction in the change from baseline in SD was observed in 
      the sitagliptin group compared with the glibenclamide group (LS mean difference 
      [95% CI]: -0.33 mmol/L [-0.62, -0.03]; P = .029). CONCLUSIONS: This study 
      suggests that the DPP4 inhibitor sitagliptin has a greater ability to reduce 
      daily glucose fluctuation than the SU glibenclamide in drug-naive Japanese 
      patients with T2DM. ClinicalTrials.gov: NCT02318693.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Suzuki, Ryo
AU  - Suzuki R
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The 
      University of Tokyo, Tokyo, Japan.
FAU - Eiki, Jun-Ichi
AU  - Eiki JI
AUID- ORCID: 0000-0002-1622-6114
AD  - Medical Affairs, and Biostatistics and Research Decision Sciences, MSD K.K, 
      Tokyo, Japan.
FAU - Moritoyo, Takashi
AU  - Moritoyo T
AD  - Phase 1 Unit, Clinical Research Support Center, The University of Tokyo Hospital, 
      Tokyo, Japan.
FAU - Furihata, Kenichi
AU  - Furihata K
AD  - P-one Clinic, Keikokai Medical Corporation, Tokyo, Japan.
FAU - Wakana, Akira
AU  - Wakana A
AD  - Medical Affairs, and Biostatistics and Research Decision Sciences, MSD K.K, 
      Tokyo, Japan.
FAU - Ohta, Yukari
AU  - Ohta Y
AD  - Medical Affairs, and Biostatistics and Research Decision Sciences, MSD K.K, 
      Tokyo, Japan.
FAU - Tokita, Shigeru
AU  - Tokita S
AD  - Medical Affairs, and Biostatistics and Research Decision Sciences, MSD K.K, 
      Tokyo, Japan.
FAU - Kadowaki, Takashi
AU  - Kadowaki T
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The 
      University of Tokyo, Tokyo, Japan.
LA  - eng
SI  - ClinicalTrials.gov/NCT02318693
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180611
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - SX6K58TVWC (Glyburide)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Aged
MH  - Blood Glucose/*analysis
MH  - Blood Glucose Self-Monitoring
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/administration & dosage
MH  - Drug Administration Schedule
MH  - Fasting/blood
MH  - Female
MH  - Glyburide/*administration & dosage
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Sitagliptin Phosphate/*administration & dosage
MH  - Sulfonylurea Compounds/administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - continuous glucose monitoring
OT  - daily glucose fluctuation
OT  - glibenclamide
OT  - sitagliptin
OT  - type 2 diabetes mellitus
EDAT- 2018/05/18 06:00
MHDA- 2019/02/06 06:00
CRDT- 2018/05/18 06:00
PHST- 2018/01/18 00:00 [received]
PHST- 2018/04/29 00:00 [revised]
PHST- 2018/05/13 00:00 [accepted]
PHST- 2018/05/18 06:00 [pubmed]
PHST- 2019/02/06 06:00 [medline]
PHST- 2018/05/18 06:00 [entrez]
AID - 10.1111/dom.13364 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 Sep;20(9):2274-2281. doi: 10.1111/dom.13364. Epub 2018 
      Jun 11.